Cargando…
A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer
Adenylate cyclase 1 (ADCY1 or AC1) is a member of ADCY superfamily and was primarily found to be expressed in the brain. ADCY1 is responsible for catalyzing ATP to cyclic AMP (cAMP). As a secondary messenger, cAMP can regulate plenty of cellular activities. cAMP can perform its regulation in cellula...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909948/ https://www.ncbi.nlm.nih.gov/pubmed/31839819 http://dx.doi.org/10.7150/jca.36614 |
_version_ | 1783479025661902848 |
---|---|
author | Zou, Ting Liu, Junyan She, Li Chen, Juan Zhu, Tao Yin, Jiye Li, Xi Li, Xiangping Zhou, Honghao Liu, Zhaoqian |
author_facet | Zou, Ting Liu, Junyan She, Li Chen, Juan Zhu, Tao Yin, Jiye Li, Xi Li, Xiangping Zhou, Honghao Liu, Zhaoqian |
author_sort | Zou, Ting |
collection | PubMed |
description | Adenylate cyclase 1 (ADCY1 or AC1) is a member of ADCY superfamily and was primarily found to be expressed in the brain. ADCY1 is responsible for catalyzing ATP to cyclic AMP (cAMP). As a secondary messenger, cAMP can regulate plenty of cellular activities. cAMP can perform its regulation in cellular transport through the binding to cAMP dependent protein kinases (PKAs), cAMP-activated guanine exchange factors (EPACs) and cyclic nucleotide-gated channels functioning in transduction of sensory signals (CNGs). Lung cancer is one of the leading factors of cancer-related death worldwide. Platinum-based chemotherapy is the first-line treatment for advanced lung cancer patients. In addition, surgical treatment, radiation treatment, and molecular targeted therapy are also therapeutic options for lung cancer patients in clinical settings. However, drug resistance and toxicity are the major obstacles that affect chemotherapy outcome and prognosis of lung cancer patients. And the therapeutic efficiency and adverse effects are varying with each individual. In recent years, investigations based on genetic sequencing have revealed the emerging role of ADCY1 mutations in affecting drug efficiency in various cancers such as lung cancer, esophageal cancer and colorectal cancer. The potential function of ADCY1 in chemotherapy resistance is of great importance to be noticed and investigated. |
format | Online Article Text |
id | pubmed-6909948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-69099482019-12-15 A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer Zou, Ting Liu, Junyan She, Li Chen, Juan Zhu, Tao Yin, Jiye Li, Xi Li, Xiangping Zhou, Honghao Liu, Zhaoqian J Cancer Review Adenylate cyclase 1 (ADCY1 or AC1) is a member of ADCY superfamily and was primarily found to be expressed in the brain. ADCY1 is responsible for catalyzing ATP to cyclic AMP (cAMP). As a secondary messenger, cAMP can regulate plenty of cellular activities. cAMP can perform its regulation in cellular transport through the binding to cAMP dependent protein kinases (PKAs), cAMP-activated guanine exchange factors (EPACs) and cyclic nucleotide-gated channels functioning in transduction of sensory signals (CNGs). Lung cancer is one of the leading factors of cancer-related death worldwide. Platinum-based chemotherapy is the first-line treatment for advanced lung cancer patients. In addition, surgical treatment, radiation treatment, and molecular targeted therapy are also therapeutic options for lung cancer patients in clinical settings. However, drug resistance and toxicity are the major obstacles that affect chemotherapy outcome and prognosis of lung cancer patients. And the therapeutic efficiency and adverse effects are varying with each individual. In recent years, investigations based on genetic sequencing have revealed the emerging role of ADCY1 mutations in affecting drug efficiency in various cancers such as lung cancer, esophageal cancer and colorectal cancer. The potential function of ADCY1 in chemotherapy resistance is of great importance to be noticed and investigated. Ivyspring International Publisher 2019-11-01 /pmc/articles/PMC6909948/ /pubmed/31839819 http://dx.doi.org/10.7150/jca.36614 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Review Zou, Ting Liu, Junyan She, Li Chen, Juan Zhu, Tao Yin, Jiye Li, Xi Li, Xiangping Zhou, Honghao Liu, Zhaoqian A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer |
title | A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer |
title_full | A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer |
title_fullStr | A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer |
title_full_unstemmed | A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer |
title_short | A perspective profile of ADCY1 in cAMP signaling with drug-resistance in lung cancer |
title_sort | perspective profile of adcy1 in camp signaling with drug-resistance in lung cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6909948/ https://www.ncbi.nlm.nih.gov/pubmed/31839819 http://dx.doi.org/10.7150/jca.36614 |
work_keys_str_mv | AT zouting aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT liujunyan aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT sheli aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT chenjuan aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT zhutao aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT yinjiye aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT lixi aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT lixiangping aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT zhouhonghao aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT liuzhaoqian aperspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT zouting perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT liujunyan perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT sheli perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT chenjuan perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT zhutao perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT yinjiye perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT lixi perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT lixiangping perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT zhouhonghao perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer AT liuzhaoqian perspectiveprofileofadcy1incampsignalingwithdrugresistanceinlungcancer |